CClinicalTrials.gg
Sign In
RecruitingNCT05929144IRMtestsUpdated Jul 3, 2023

Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases

An interventional study of MRI sequences testing in Memory Disorders, sponsored by University Hospital, Caen. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Other

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases.

Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images.

In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.

02

Conditions studied

  • Memory Disorders
03

In context

Neurodegenerative Diseases

370 studies on the registry are indexed under Neurodegenerative Diseases; 145 are open to participants now.

This study's planned enrollment of 40 is below the median of 53 across 204 interventional studies indexed under Neurodegenerative Diseases.

Browse Neurodegenerative Diseases studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 505 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy volunteers of legal age
  • Affiliation with a social security scheme or beneficiary of such a scheme
  • Signing of the protocol informed consent
  • For women of childbearing age or capacity, a urine pregnancy test before inclusion

Exclusion criteria

Exclusion Criteria:

  • Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women
  • Presence of contraindications to MRI examination without contrast agents injection
  • Presence of a chronic neurological or psychiatric condition (including substance use disorder)
  • History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)
  • Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Healthy volunteers

    Other: MRI sequences testing

Interventions

  • OtherMRI sequences testing

    Testing different MRI sequences in order to optimize them

06

What researchers measure

Primary outcomes

  1. Optimization of MRI sequences

    TR, TE, Flip Angle, asset phase, asset slice parameters

    Time frame: During MRI sessions

07

Study locations

1 of 1 sites recruiting
  • GIP Cyceron
    Caen, 14000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929144
Lead sponsor
University Hospital, Caen
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
May 5, 2023
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 3, 2023

Study contacts

Géraldine Poisnel, PhD
Contact
poisnel@cyceron.fr
0231470206
Gaël Chételat, PhD
study director · Institut National de la Santé Et de la Recherche Médicale, France
Nicolas Cabé, MD, PhD
principal investigator · CHU Caen Normandie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neurodegenerative Diseases→

Other studies from this sponsor

University Hospital, Caen

Start the discussion